ReviewFrontiers in immunology2026

Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection.

Xi Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.